Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings

Abstract

The sorafenib safety profile in European community-based practice settings was similar to that reported in clinical trials. The heterogeneous advanced RCC patient population in EU-ARCCS permitted assessment of sorafenib in important subpopulations of advanced RCC patients.

Sorafenib-induced reversible posterior leukoencephalopathy in patients with renal cell carcinoma: A report of two cases

“…As sorafenib is widely used in the treatment of RCC, hepatocellular carcinoma and thyroid carcinoma (17)(18)(19)(20)(21)(22), the oncology community should be alerted to this uncommon but life-threatening adverse event.…”

New Systemic Approaches in the Treatment of Metastatic Renal Cell Carcinoma

“…(Escudier et al, 2007b) This was consistent with an earlier phase II second line trial that found PFS benefit was independent of age over or under 70 years, prognostic risk, prior cytokine therapy, lung, liver, bone or brain metastases, time from diagnosis, or whether or not the patient had clinical cardiovascular disease. (Beck et al, 2011;Escudier et al, 2007b) The latter included patients with ischemic heart disease, a previous myocardial infarction, left ventricular dysfunction, hypertension, epistaxis or central nervous system ischemia. (Beck et al, 2011) Patients on the placebo arm were permitted to cross over to sorafenib on diagnosis of progressive disease.…”

“…(Beck et al, 2011;Escudier et al, 2007b) The latter included patients with ischemic heart disease, a previous myocardial infarction, left ventricular dysfunction, hypertension, epistaxis or central nervous system ischemia. (Beck et al, 2011) Patients on the placebo arm were permitted to cross over to sorafenib on diagnosis of progressive disease. In the first interim analysis, a trend towards better OS was noted in patients taking sorafenib, and this was unchanged in the final analysis (17.8 vs. 15.2 months, respectively, HR= 0.88; p = 0.146).…”

Sequential Use of Targeted Therapies (TT) in Metastatic Renal Cell Cancer (mRCC): Overall Results of a Large Experience

“…Clinical evidence supports the efficacy of sequential treatment with SU/SO [19]; however, the optimal sequence for SO and SU is still under debate, and additional evidence on the optimal use of sequential targeted therapies is advocated.…”